These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22052407)

  • 1. Optimal sample sizes for phase II clinical trials and pilot studies.
    Stallard N
    Stat Med; 2012 May; 31(11-12):1031-42. PubMed ID: 22052407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample sizes for phase II clinical trials derived from Bayesian decision theory.
    Brunier HC; Whitehead J
    Stat Med; 1994 Dec 15-30; 13(23-24):2493-502. PubMed ID: 7701149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-theoretic designs for small trials and pilot studies: A review.
    Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
    Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility-based optimization of phase II/III programs.
    Kirchner M; Kieser M; Götte H; Schüler A
    Stat Med; 2016 Jan; 35(2):305-16. PubMed ID: 26256550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian decision approach for sample size determination in phase II trials.
    Leung DH; Wang YG
    Biometrics; 2001 Mar; 57(1):309-12. PubMed ID: 11252615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical challenges in assessing potential efficacy of complex interventions in pilot or feasibility studies.
    Wilson DT; Walwyn RE; Brown J; Farrin AJ; Brown SR
    Stat Methods Med Res; 2016 Jun; 25(3):997-1009. PubMed ID: 26071430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision theoretic designs for phase II clinical trials with multiple outcomes.
    Stallard N; Thall PF; Whitehead J
    Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of predictive probabilities in phase II and phase III clinical trials.
    Johns D; Andersen JS
    J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal choice of the number of treatments to be included in a clinical trial.
    Stallard N; Posch M; Friede T; Koenig F; Brannath W
    Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules.
    Zohar S; Latouche A; Taconnet M; Chevret S
    Comput Methods Programs Biomed; 2003 Oct; 72(2):117-25. PubMed ID: 12941516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.